Clinical efficacy of lenalidomide in fludarabine-refractory chronic lymphocytic leukemia patients.

被引：4
|
作者：
Chanan-Khan, AsherA. [1 ]
Czuczman, Myron S. [1 ]
Padmanabhan, Swarminathan [1 ]
Keating, Michael J. [2 ]
O'Brien, Susan M. [2 ]
Wierda, William G. [2 ]
Ferrajoli, Alessandra [2 ]
机构：
[1] Roswell Pk Canc Inst, Buffalo, NY USA
[2] MD Anderson Canc Ctr, Houston, TX USA
来源：
BLOOD | 2007年 / 110卷 / 11期
关键词：
D O I：
10.1182/blood.V110.11.3108.3108
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3108
引用
收藏
页码：914A / 914A
页数：1
相关论文
共 50 条
  • [31] Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia
    Tsimberidou, Apostolia M.
    Wierda, William G.
    Plunkett, William
    Kurzrock, Razelle
    O'Brien, Susan
    Wen, Sijin
    Ferrajoli, Alessandra
    Ravandi-Kashani, Farhad
    Garcia-Manero, Guillermo
    Estrov, Zeev
    Kipps, Thomas J.
    Brown, Jennifer R.
    Fiorentino, Albert
    Lerner, Susan
    Kantarjian, Hagop M.
    Keating, Michael J.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (02) : 196 - 203
  • [32] Phase II study of single-agent bortezomib for the treatment of patients with fludarabine-refractory B-cell chronic lymphocytic leukemia
    Faderl, Stefan
    Rai, Kanti
    Gribben, John
    Byrd, John C.
    Flinn, Ian W.
    O'Brien, Susan
    Sheng, Shihong
    Esseltine, Dixie-Lee
    Keating, Michael J.
    CANCER, 2006, 107 (05) : 916 - 924
  • [33] Final results of EFC6663: A multicenter, international, phase 2 study of alvocidib for patients with fludarabine-refractory chronic lymphocytic leukemia
    Lanasa, Mark C.
    Andritsos, Leslie
    Brown, Jennifer R.
    Gabrilove, Janice
    Caligaris-Cappio, Federico
    Ghia, Paolo
    Larson, Richard A.
    Kipps, Thomas J.
    Leblond, Veronique
    Milligan, Donald W.
    Janssens, Ann
    Johnson, Amy J.
    Heerema, Nyla A.
    Buehler, Andreas
    Stilgenbauer, Stephan
    Devin, Jeanne
    Hallek, Michael
    Byrd, John C.
    Grever, Michael R.
    LEUKEMIA RESEARCH, 2015, 39 (05) : 495 - 500
  • [34] Subcutaneous Alemtuzumab in Fludarabine-Refractory Chronic Lymphocytic Leukemia: Clinical Results and Prognostic Marker Analyses From the CLL2H Study of the German Chronic Lymphocytic Leukemia Study Group
    Stilgenbauer, Stephan
    Zenz, Thorsten
    Winkler, Dirk
    Buehler, Andreas
    Schlenk, Richard F.
    Groner, Silja
    Busch, Raymonde
    Hensel, Manfred
    Duehrsen, Ulrich
    Finke, Juergen
    Dreger, Peter
    Jaeger, Ulrich
    Lengfelder, Eva
    Hohloch, Karin
    Soeling, Ulrike
    Schlag, Rudolf
    Kneba, Michael
    Hallek, Michael
    Doehner, Hartmut
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (24) : 3994 - 4001
  • [35] Activity of ofatumumab, a novel CD20 mAb, and prior rituximab exposure in patients with fludarabine- and alemtuzumab-refractory or bulky fludarabine-refractory chronic lymphocytic leukemia (CLL)
    Wierda, W. G.
    Kipps, T.
    Mayer, J.
    Stilgenbauer, S.
    Robak, T.
    Williams, C. D.
    Furman, R.
    Chan, G.
    Russell, C.
    Osterborg, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [36] MicroRNAs involvement in fludarabine refractory chronic lymphocytic leukemia
    Manuela Ferracin
    Barbara Zagatti
    Lara Rizzotto
    Francesco Cavazzini
    Angelo Veronese
    Maria Ciccone
    Elena Saccenti
    Laura Lupini
    Andrea Grilli
    Cristiano De Angeli
    Massimo Negrini
    Antonio Cuneo
    Molecular Cancer, 9
  • [37] MicroRNAs involvement in fludarabine refractory chronic lymphocytic leukemia
    Ferracin, Manuela
    Zagatti, Barbara
    Rizzotto, Lara
    Cavazzini, Francesco
    Veronese, Angelo
    Ciccone, Maria
    Saccenti, Elena
    Lupini, Laura
    Grilli, Andrea
    De Angeli, Cristiano
    Negrini, Massimo
    Cuneo, Antonio
    MOLECULAR CANCER, 2010, 9
  • [38] LenD: a study to establish the safety and efficacy of lenalidomide and dexamethasone in patients with relapsed or refractory chronic lymphocytic leukemia
    Gohil, Satyen Harish
    Maciocia, Nicola
    Patrick, Pip
    Roberts, Thomas
    Counsell, Nicholas
    Smith, Paul
    Clifton-Hadley, Laura
    Cwynarski, Kate
    Pettitt, Andrew
    Nathwani, Amit Chunilal
    LEUKEMIA & LYMPHOMA, 2018, 59 (07) : 1730 - 1733
  • [39] Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma - Implications for clinical trials in this patient population
    Perkins, JG
    Flynn, JM
    Howard, RS
    Byrd, JC
    CANCER, 2002, 94 (07) : 2033 - 2039
  • [40] Outcomes of patients with fludarabine-refractory chronic lymphocytic leukemia: a population-based study from a well-defined geographic region
    Sylvan, Sandra Eketorp
    Hansson, Lotta
    Karlsson, Claes
    Norin, Stefan
    Lundin, Jeanette
    Osterborg, Anders
    LEUKEMIA & LYMPHOMA, 2014, 55 (08) : 1774 - 1780
12345